Active Surveillance In Intermediate-Risk Prostate Cancer Called Into Question.
Dr. Israel Barken brings info about higher risk of cancer specific mortality in the intermediate prostate cancer risk group. The study presentor at the GenitoUrinary Symposium 2015 was Dr. Andrew Loblaw. The study was conducted at the Sunnybrook Health Sciences Center. The risk of prostate cancer-specific death at 15 years was 3.75 times higher for intermediate risk patients compared to patients with low risk patients.
Source: ASCO POST March , 2015